Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to 22.66%.

  • Gyre Therapeutics' EBITDA Margin rose 605.00% to 22.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.22%, marking a year-over-year increase of 8370.00%. This contributed to the annual value of 15.28% for FY2024, which is 7454.00% up from last year.
  • Gyre Therapeutics' EBITDA Margin amounted to 22.66% in Q3 2025, which was up 179.39% from 8.11% recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' EBITDA Margin registered a high of 39.84% during Q3 2023, and its lowest value of -1,851.51% during Q1 2022.
  • Over the past 3 years, Gyre Therapeutics' median EBITDA Margin value was 16.61% (recorded in 2024), while the average stood at -13.78%.
  • Per our database at Business Quant, Gyre Therapeutics' EBITDA Margin slumped by 149,855bps in 2021 and then soared by 187,824bps in 2023.
  • Over the past 5 years, Gyre Therapeutics' EBITDA Margin (Quarterly) stood at -832.50% in 2021, then soared by 81,037bps to -22.13% in 2022, then crashed by 31,540bps to -337.53% in 2023, then surged by 33,991bps to 2.39% in 2024, then spiked by 605bps to 22.66% in 2025.
  • Its EBITDA Margin stands at 22.66% for Q3 2025, versus 8.11% for Q2 2025 and 10.30% for Q1 2025.